TARS

AI MemoPost-earnings T+3

Tarsus

As of 2026-08-08/Post-earnings T+3/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

Post-earnings digestion of raised XDEMVY outlook • 2026-08-11

Base target: $75 / p=50% prob

Biggest risk

The post-print share reaction was negative despite strong reported sales, while the Alkeus transaction introduces acquisition, financing, dilution, and execution risk. R&D expense increased to $31.0 million from $15.6 million, primarily reflecting TP-05 and other program spending. Verified post-print analyst target changes and estimate revisions remain unavailable.

Invalidation

Break below $52 or thesis failure.

What would change my mind?

The company-source earnings update strengthens the commercial thesis: XDEMVY sales reached $173.9 million, ECP prescribing depth improved, guidance was raised, and the Alkeus agreement adds a late-stage retina asset. [#SEC-8K-2026-08-06](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000063/exhibit991tarsus862026.htm)

Research note

Recommendation

—

Confidence

medium

As of

2026-08-08

Base target

$75

p=50%

Bull target

$95

p=30%

Bear target

$52

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Continued XDEMVY commercial uptake
Alkeus acquisition and Stargardt pipeline expansion
The company-source earnings update strengthens the commercial thesis: XDEMVY sales reached $173.9 million, ECP prescribing depth improved, guidance was raised, and the Alkeus agreement adds a late-stage retina asset.

BearKey bullets

R&D expense more than doubled year over year as pipeline investment increased, while the earnings release did not provide a verified cash-runway assessment in the available excerpt.
[#SEC-8K-2026-08-06](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000063/exhibit991tarsus862026.htm)
Recent open-market sales by the CEO and directors are a negative sentiment input but do not establish operating deterioration.

WatchKey bullets

Post-earnings digestion of raised XDEMVY outlook

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Post-earnings T+3

Base case: $75 (p=50%)

Target spread vs base: +27% / -31%

Scenario probabilities

Bull Target: $95 (p=30%)Base Target: $75 (p=50%)Bear Target: $52 (p=20%)

Commentary

The company-source earnings release provides concrete support for strong sales, adoption, guidance, and pipeline execution. The RankAlpha anchor price was $64.79 on August 7, while secondary coverage quoted shares down about 5.1%; the exact pre-print benchmark and timing are not independently clear. The latest surfaced analyst action predates the print, and no verified post-earnings target or estimate revisions were found. Social coverage is unavailable, so the appropriate stance remains cautious monitoring rather than high-conviction positioning. [MarketBeat](https://www.marketbeat.com/earnings/reports/2026-8-6-tarsus-pharmaceuticals-inc-stock/)

As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Continued XDEMVY commercial uptake
Alkeus acquisition and Stargardt pipeline expansion

Scenarios

Bull Target (Scenario probability)

$95 / p=30% prob

Base Target (Scenario probability)

$75 / p=50% prob

Bear Target (Scenario probability)

$52 / p=20% prob

Analysis 2026-08-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-08-11
Post-earnings digestion of raised XDEMVY outlook
Q2 2026 XDEMVY net product sales were $173.9 million, up more than 69% year over year, with growth driven by higher volume and improved gross-to-net discounts. Full-year 2026 guidance increased to $685–705 million from $670–700 million; verified EPS and revenue surprise versus consensus remain unavailable. [#SEC-8K-2026-08-06](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000063/exhibit991tarsus862026.htm)
Prob 75.00% • Move 7.00% • Priced-in 80.00%
EVENT2026-11-06
TP-04 and TP-05 Phase 2 data
The TP-04 KORE trial continues to progress and TP-05 Calliope completed enrollment; topline data for both programs is expected in the first half of 2027. [#SEC-8K-2026-08-06](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000063/exhibit991tarsus862026.htm)
Prob 55.00% • Move 18.00% • Priced-in 20.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Continued XDEMVY commercial uptake
2027-08-08
The company reported that ECPs prescribing XDEMVY five or more times weekly doubled year over year, supporting continued commercial execution. Gross margin remained approximately 93%, but sustained demand and repeatability of volume and gross-to-net benefits remain key monitoring points. [#SEC-8K-2026-08-06](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000063/exhibit991tarsus862026.htm)
Prob 70% • Move 14% • Priced-in 65%
Alkeus acquisition and Stargardt pipeline expansion
2027-08-08
Tarsus entered into an agreement to acquire Alkeus Pharmaceuticals, adding ALK-001 and a Phase 3 Stargardt program; the transaction includes a $125 million private placement. Closing timing and execution milestones were not specified in the available excerpt. [#SEC-8K-2026-08-06](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000063/exhibit991tarsus862026.htm)
Prob 55% • Move 15% • Priced-in 50%

Risks

R&D expense more than doubled year over year as pipeline investment increased, while the earnings release did not provide a verified cash-runway assessment in the available excerpt. [#SEC-8K-2026-08-06](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000063/exhibit991tarsus862026.htm)
Recent open-market sales by the CEO and directors are a negative sentiment input but do not establish operating deterioration. [#SEC-FORM4-2026-06-22](https://www.sec.gov/Archives/edgar/data/1819790/000182767226000009/wk-form4_1782158996.xml)
TP-04, TP-05, and the acquired Stargardt program remain subject to clinical, regulatory, enrollment, and readout risk.
The pending Alkeus acquisition and $125 million private placement create capital-allocation, dilution, integration, and clinical execution risks. [#SEC-8K-2026-08-06](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000063/exhibit991tarsus862026.htm)
XDEMVY remains the central commercial driver, leaving execution and demand expectations vulnerable if growth, prescribing depth, volume, or gross-to-net performance slows.

Peers

Symbol	Summary
BEAM	Loose same-sector biotech reference with a different modality and development profile; not a direct operating comparator.
IOVA	Same-sector commercial-stage biotech reference, but not a direct eye-care or indication peer.
KOD	The closest available ophthalmology-oriented reference, but the packet does not establish sufficient indication-level or commercial comparability.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-08

Loading AI feed…

Symbol

Summary

BEAM

Loose same-sector biotech reference with a different modality and development profile; not a direct operating comparator.

IOVA

Same-sector commercial-stage biotech reference, but not a direct eye-care or indication peer.

KOD

The closest available ophthalmology-oriented reference, but the packet does not establish sufficient indication-level or commercial comparability.